Article
Real-World Use of Highly Sensitive Liquid Biopsy Monitoring in Metastatic Breast Cancer Patients Treated with Endocrine Agents after Exposure to Aromatase Inhibitors.
International journal of molecular sciences - 13 Jul 2023
Fuentes-Antrás Jesús, Martínez-Rodríguez Ana, Guevara-Hoyer Kissy, López-Cade Igor, Lorca Víctor, Pascual Alejandro, de Luna Alicia, Ramírez-Ruda Carmen, Swindell Jennifer, Flores Paloma, Lluch Ana, Cescon David W, Pérez-Segura Pedro, Ocaña Alberto, Jones Frederick, Moreno Fernando, García-Barberán Vanesa, García-Sáenz José Ángel
Abstract excerpt
Endocrine-resistant, hormone receptor-positive, and HER2-negative (HR+/HER2-) metastatic breast cancer (mBC) is largely governed by acquired mutations in the estrogen receptor, which promote ligand-independent activation, and by truncal alterations in the PI3K signaling pathway, with a broader range of gene alterations occurring with less prevalence. Circulating tumor DNA (ctDNA)-based technologies are...
Topics
- Female
- Humans
- Antineoplastic Combined Chemotherapy Protocols
- Aromatase Inhibitors
- Breast Neoplasms
- Class I Phosphatidylinositol 3-Kinases
- Liquid Biopsy
- Phosphatidylinositol 3-Kinases